| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDH19 |
| Uniprot No | Q9H159 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-772aa |
| 氨基酸序列 | MNCYLLLRFMLGIPLLWPCLGATENSQTKKVKQPVRSHLRVKRGWVWNQFFVPEEMNTTSHHIGQLRSDLDNGNNSFQYKLLGAGAGSTFIIDERTGDIYAIQKLDREERSLYILRAQVIDIATGRAVEPESEFVIKVSDINDNEPKFLDEPYEAIVPEMSPEGTLVIQVTASDADDPSSGNNARLLYSLLQGQPYFSVEPTTGVIRISSKMDRELQDEYWVIIQAKDMIGQPGALSGTTSVLIKLSDVNDNKPIFKESLYRLTVSESAPTGTSIGTIMAYDNDIGENAEMDYSIEEDDSQTFDIITNHETQEGIVILKKKVDFEHQNHYGIRAKVKNHHVPEQLMKYHTEASTTFIKIQVEDVDEPPLFLLPYYVFEVFEETPQGSFVGVVSATDPDNRKSPIRYSITRSKVFNINDNGTITTSNSLDREISAWYNLSITATEKYNIEQISSIPLYVQVLNINDHAPEFSQYYETYVCENAGSGQVIQTISAVDRDESIEEHHFYFNLSVEDTNNSSFTIIDNQDNTAVILTNRTGFNLQEEPVFYISILIADNGIPSLTSTNTLTIHVCDCGDSGSTQTCQYQELVLSMGFKTEVIIAILICIMIIFGFIFLTLGLKQRRKQILFPEKSEDFRENIFQYDDEGGGEEDTEAFDIAELRSSTIMRERKTRKTTSAEIRSLYRQSLQVGPDSAIFRKFILEKLEEANTDPCAPPFDSLQTYAFEGTGSLAGSLSSLESAVSDQDESYDYLNELGPRFKRLACMFGSAVQSNN |
| 分子量 | 113.4 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组人钙粘蛋白-19(CDH19)的模拟参考文献概括(具体文献需通过学术数据库核实)：
1. **文献名称**：《CDH19在黑色素瘤侵袭中的调控作用》
**作者**：Smith A et al.
**摘要**：研究发现CDH19通过激活PI3K/AKT信号通路促进黑色素瘤细胞迁移和侵袭，其高表达与患者预后不良相关。
2. **文献名称**：《CDH19基因突变与神经发育障碍的关联》
**作者**：Chen L et al.
**摘要**：首次报道CDH19突变导致X-linked癫痫和智力障碍，通过破坏神经元迁移和突触形成影响大脑发育。
3. **文献名称**：《靶向CDH19的抗体药物偶联物在实体瘤治疗中的应用》
**作者**：Wang Y et al.
**摘要**：开发靶向CDH19的ADC药物，体外实验显示对CDH19高表达的乳腺癌和卵巢癌细胞具有特异性杀伤作用。
4. **文献名称**：《CDH19与Wnt/β-catenin通路的交互机制》
**作者**：Garcia R et al.
**摘要**：揭示了CDH19通过稳定β-catenin蛋白增强结直肠癌细胞干性，提示其可能作为癌症干细胞标志物。
(注：以上为文献研究方向示例，实际文献需通过PubMed、Google Scholar等平台检索确认。)
Recombinant human Cadherin-19 (CDH19) is a calcium-dependent cell adhesion molecule belonging to the cadherin superfamily, specifically classified within the type II classical cadherins. It plays a critical role in mediating cell-cell interactions through homophilic binding, contributing to tissue morphogenesis and neural circuit organization. Structurally, CDH19 features extracellular cadherin repeats, a transmembrane domain, and a cytoplasmic tail that interacts with intracellular catenins to regulate signaling pathways.
CDH19 is prominently expressed during embryonic development, particularly in the nervous system, where it influences neural crest cell migration, axon guidance, and synaptic connectivity. Aberrant CDH19 expression has been linked to pathologies, including neurodevelopmental disorders and cancers. Notably, CDH19 mutations are associated with epilepsy and intellectual disabilities, often with female predominance due to its X-chromosomal location (Xq13.1). In oncology, CDH19 is implicated in tumor progression and metastasis in melanoma, neuroblastoma, and breast cancer, where it may modulate epithelial-mesenchymal transition (EMT) and drug resistance.
Recombinant CDH19. produced via genetic engineering in mammalian or bacterial systems, serves as a vital tool for studying adhesion mechanisms, screening therapeutic antibodies, or exploring targeted therapies. Its role in disease pathways continues to drive research into diagnostic and therapeutic applications. (Word count: 200)
×
